1. Home
  2. FOLD vs PBH Comparison

FOLD vs PBH Comparison

Compare FOLD & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • PBH
  • Stock Information
  • Founded
  • FOLD 2002
  • PBH 1996
  • Country
  • FOLD United States
  • PBH United States
  • Employees
  • FOLD N/A
  • PBH N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • PBH Biotechnology: Pharmaceutical Preparations
  • Sector
  • FOLD Health Care
  • PBH Health Care
  • Exchange
  • FOLD Nasdaq
  • PBH Nasdaq
  • Market Cap
  • FOLD 2.9B
  • PBH 3.3B
  • IPO Year
  • FOLD 2007
  • PBH 2005
  • Fundamental
  • Price
  • FOLD $7.58
  • PBH $68.07
  • Analyst Decision
  • FOLD Strong Buy
  • PBH Buy
  • Analyst Count
  • FOLD 10
  • PBH 5
  • Target Price
  • FOLD $26.89
  • PBH $94.00
  • AVG Volume (30 Days)
  • FOLD 3.8M
  • PBH 601.1K
  • Earning Date
  • FOLD 07-31-2025
  • PBH 08-07-2025
  • Dividend Yield
  • FOLD N/A
  • PBH N/A
  • EPS Growth
  • FOLD N/A
  • PBH 4.18
  • EPS
  • FOLD N/A
  • PBH 4.26
  • Revenue
  • FOLD $571,160,000.00
  • PBH $1,120,150,000.00
  • Revenue This Year
  • FOLD $20.98
  • PBH N/A
  • Revenue Next Year
  • FOLD $20.74
  • PBH $2.24
  • P/E Ratio
  • FOLD N/A
  • PBH $15.97
  • Revenue Growth
  • FOLD 25.35
  • PBH 0.63
  • 52 Week Low
  • FOLD $5.51
  • PBH $62.95
  • 52 Week High
  • FOLD $12.65
  • PBH $90.04
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 69.88
  • PBH 41.81
  • Support Level
  • FOLD $7.40
  • PBH $66.33
  • Resistance Level
  • FOLD $7.80
  • PBH $67.61
  • Average True Range (ATR)
  • FOLD 0.22
  • PBH 1.34
  • MACD
  • FOLD 0.01
  • PBH 0.61
  • Stochastic Oscillator
  • FOLD 87.61
  • PBH 92.81

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About PBH Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Share on Social Networks: